The Stages of Menopause

The menopause transition isn’t a single event. It’s a multi-year hormonal journey with distinct phases, each with its own biology, set of common experiences, and clinical considerations. Menopause technically refers to a single point in time, the day that marks 12 consecutive months without a menstrual period. In the strictest sense, it is one day in a woman’s entire life. In practice, the word is used loosely to describe the entire transition, the symptoms surrounding it, and the years that follow, which is why this article, like most clinical conversations, sometimes uses it in that broader sense. Most women receive very little information about what the actual phases of this transition are or how to recognize them, which makes the experience of moving through them unnecessarily confusing.

This article explains the stages of menopause, what’s happening hormonally in each, what symptoms tend to emerge and when, and what you should know about care and treatment at each phase.

What You’ll Learn in This Article

Q: What is the menopause transition, exactly?

A: The menopause transition is the years-long process through which the ovaries gradually reduce hormone production, leading eventually to the permanent end of menstrual periods. It includes several distinct stages (the late reproductive years, early and late perimenopause, and postmenopause) each with different hormonal patterns and symptoms.

Q: What’s the difference between perimenopause and menopause?

A: Menopause is a single moment in time: the point at which a woman has gone 12 full consecutive months without a menstrual period. Perimenopause is the transitional phase leading up to that point, typically lasting four to eight years, during which cycles become irregular, hormones fluctuate, and symptoms often emerge. The word itself comes from the Greek prefix peri, meaning “around” or “near”. So, perimenopause quite literally means “around menopause,” which is an accurate description of what it is.

Q: When does menopause typically begin?

A: Most women begin noticing changes in their late 30s or early 40s, though for many the more noticeable shift begins in the mid-to-late 40s. The average age of natural menopause in the U.S. is 51.4 years, and most women spend the years between roughly 45 and 52 in the most symptomatic phases of the transition. Early menopause (before age 45) and premature menopause (before age 40) affect about 10% of women and carry their own clinical considerations.

Q: Why does it matter which phase of menopause I’m in?

A: Because symptoms, treatment options, and clinical priorities differ meaningfully across phases. Early perimenopause often looks different from late perimenopause. And postmenopause introduces a new set of considerations that aren’t always on the radar during the transition itself.

Q: Is hormone therapy appropriate during all phases?

A: For most healthy women without contraindications, hormone therapy is considered appropriate and safe when initiated during perimenopause or early postmenopause, generally before age 60 or within 10 years of menopause. This timing is sometimes called the “therapeutic window,” and it’s an important concept in understanding when treatment is most beneficial.

The Staging Framework: How Clinicians Classify the Transition

The most widely accepted clinical framework for staging reproductive aging is the Stages of Reproductive Aging Workshop (STRAW +10), which divides a woman’s hormonal life into seven stages, five before the final menstrual period and two after it. Understanding this framework is genuinely useful, because it connects what you might be experiencing day-to-day to what is actually happening biologically.

The key marker used by STRAW +10 to define the beginning of menopause is a change in your menstrual cycle length. Specifically, it’s a persistent difference of 7 or more days between consecutive cycles. This variability reflects the shift in ovarian function that is the hallmark of the transition. From there, the system tracks how much further along that hormonal shift has progressed.

It’s important to note that not every woman will experience all seven stages in a textbook sequence. The duration of each phase varies widely between women, and individual experiences can look quite different from any standard description. But the framework provides a useful map.

Phase 1: The Late Reproductive Years

Before cycles become noticeably irregular, something is already shifting. In the late reproductive stage (often the late 30s and early 40s) ovarian reserve (the remaining supply of eggs) begins to decline. FSH, the hormone that signals the ovaries to develop follicles, starts to rise. Estradiol, the primary form of estrogen produced during reproductive years, may actually spike erratically before beginning its eventual decline.

For most women, this phase is subtle. Cycles may still be regular. But some women notice changes: shorter cycles than they used to have, increased premenstrual symptoms, sleep that isn’t quite as restorative, or a shift in how their bodies respond to stress. These changes are real, even if they don’t show up clearly on lab work yet.

Common symptoms in the late reproductive years

• Cycles that are slightly shorter than before (every 24-26 days rather than 28)
• Increased PMS-like symptoms
• Changes in sleep quality
• Occasional mood changes in the days before a period

Because many of these symptoms are nonspecific, they are frequently attributed to stress, work, or “just getting older.” But they often have a hormonal explanation. Recognizing them can help women begin conversations with their providers earlier rather than later.

Phase 2a: Early Perimenopause

Early perimenopause begins when cycle length starts to vary noticeably: the STRAW +10 benchmark is a persistent difference of 7 or more days between consecutive cycles. Your period might come after 21 days one month and 35 days the next. The rhythm you may have relied on for decades begins to feel unreliable.

This variability reflects the increasingly inconsistent output of the ovaries. Follicle development becomes less regular, which means ovulation is less predictable, which means progesterone, which is only produced after ovulation, becomes less consistent as well. Estrogen, meanwhile, doesn’t simply decline at this stage; it fluctuates in wide swings, sometimes surging quite high before dropping.

That combination of erratic estrogen peaks and unpredictable progesterone is what drives many of the most disruptive symptoms of this phase.

Common symptoms in early perimenopause

• Hot flashes and night sweats: Vasomotor symptoms can begin in early perimenopause. Research suggests approximately 80% of women experience them at some point during the transition, and they can begin even when cycles are still relatively regular.
• Sleep disruption: Often linked to both night sweats and direct hormonal effects on sleep architecture. Women typically report poorer sleep quality during perimenopause than during the late reproductive years.
• Mood changes: Well-designed longitudinal studies have found a 2- to 5-fold higher risk of major depressive episodes during perimenopause compared to the late reproductive years. Anxiety symptoms are also common and tend to peak during late perimenopause.
• Heavy or irregular periods: When ovulation doesn’t occur, progesterone doesn’t rise to stabilize the uterine lining. The result is often a heavier-than-normal period when it finally does arrive. Heavy periods are among the most disruptive and least-discussed symptoms of early perimenopause.
• Cognitive changes: Many women report word-finding difficulty, forgetfulness, and reduced ability to concentrate. These cognitive changes are real and hormonal in origin for many women, though they are frequently dismissed or attributed to other causes.

One important point: pregnancy is still possible during early perimenopause. Even with irregular cycles, ovulation can occur. Women who do not wish to become pregnant should continue using contraception until 12 consecutive months have passed without a period.

Phase 2b: Late Perimenopause

Late perimenopause is defined by an interval of amenorrhea, defined as at least 60 days without a period. Cycles have become long and unpredictable, ovulation is rare, and the hormonal shifts are more pronounced. This is often the most symptomatic phase of the menopause transition, and it can last one to three years before menopause is reached.

Estradiol levels begin their more sustained decline during this stage, though they can still fluctuate considerably. FSH rises further. The progesterone deficit is more consistent now, which contributes to anovulatory cycles, defined as cycles in which menstruation occurs but no ovulation takes place.

Common symptoms in late perimenopause

• Hot flashes and night sweats: Vasomotor symptoms tend to be most frequent and intense during this phase. Research has identified four distinct patterns of symptom trajectory, underscoring that each woman’s experience is genuinely individual. Total duration can extend 7 to 10 years or more, and for women whose symptoms begin early in the transition, the duration tends to be longer.
• Depression and anxiety: Both tend to peak during late perimenopause, then decline after menopause. Mental health tends to be multi-faceted, and during the late perimenopause years, women are often under a lot of stress and experiencing life changes such as the loss of a parent. But, hormonal changes are a real contributor to changes in mood and outlook and should be addressed, along with other forms of mental health treatment.
• Body composition changes: Weight and body composition shift in ways that feel different from ordinary aging. Research from the SWAN study found that lean mass declines and total fat mass increases more rapidly during the menopausal transition than during either the premenopausal or postmenopausal phases. Abdominal fat in particular increases notably during this time, a pattern driven by hormonal changes rather than simply caloric intake or reduced activity. This shift of fat toward the abdomen and away from the hips and thighs carries distinct metabolic implications, including increased cardiovascular and insulin resistance risk, independent of total body weight. Many women find that approaches to diet and exercise that worked previously become less effective during this phase, which is a physiological reality, not a failure of effort.
• Genitourinary symptoms: Vaginal dryness, changes in bladder function, and urinary urgency or frequency may begin in late perimenopause and are likely to intensify after menopause. Unlike hot flashes, which often improve over time on their own, genitourinary symptoms tend to be progressive if untreated.
• Heavy menstrual bleeding: Heavy menstrual bleeding, clinically defined as soaking through a pad or tampon every hour for two or more consecutive hours, or passing clots larger than a quarter, is common in late perimenopause and is directly linked to the progesterone deficiency that accompanies anovulatory cycles. When ovulation doesn’t occur, progesterone doesn’t rise to stabilize the uterine lining, which builds up more than usual and sheds heavily. Some women also experience more frequent periods at this stage, which compounds total monthly blood loss.

Phase 2: Menopause

Menopause is defined as the point at which a woman has gone 12 full consecutive months without a menstrual period, in the absence of other medical causes. It is not a phase: it is a single moment in time, and importantly, you can only know you’ve reached it in retrospect.

The average age of natural menopause in the United States is 51.4 years. Menopause before age 45 is considered early menopause; before age 40 is premature menopause (also called primary ovarian insufficiency, or POI). Approximately 10% of women reach menopause before age 45. For women in this category, the clinical considerations are meaningfully different. Earlier and longer estrogen deficiency carries greater risks for bone loss, cardiovascular disease, cognitive changes, and overall health outcomes, making hormone therapy discussions especially important.

Menopause can also occur surgically (following removal of both ovaries) or as a result of chemotherapy or radiation. Surgical menopause is abrupt rather than gradual, and the immediate hormonal shift is often more intense than natural menopause, which is why symptoms following surgical menopause tend to be more severe.

Phase 3: Postmenopause

Once 12 months have passed without a period, a woman enters postmenopause, where she will remain for the rest of her life. It’s important to recognize that this is not the end of the conversation about hormonal health: in some ways, it’s the beginning of a new chapter of it.

In early postmenopause (generally the first three to four years after the final menstrual period), vasomotor symptoms and mood changes that were prominent in perimenopause often continue and may remain intense. FSH levels have stabilized at a consistently elevated level. Estradiol has reached a new, much lower baseline.

With the average U.S. woman living to 81, many women will spend 30 or more years in postmenopause. What happens hormonally in this phase has real, long-term consequences for health.

Common health considerations in postmenopause

Genitourinary health

One of the most significant impacts of sustained estrogen deficiency is genitourinary syndrome of menopause (GSM). Symptoms include vaginal dryness, irritation, and discomfort with intercourse; recurrent urinary tract infections; urinary urgency, frequency, and leakage; and changes in pelvic floor function.

Unlike hot flashes, which for many women improve over time, GSM is a progressive condition. It typically worsens the longer a woman goes without estrogen, and it does not resolve on its own. The good news is that it is highly treatable: local, low-dose vaginal estrogen is the most effective treatment and carries no meaningful systemic absorption or cancer risk at recommended doses, according to current clinical guidelines.

Bone density

The first several years after menopause represent the window of greatest bone density loss. Bone loss accelerates significantly during the menopause transition and continues into postmenopause because estrogen plays a critical protective role in bone metabolism, and its decline triggers an accelerated period of bone resorption. Over time, this increases fracture risk; hip fractures in particular carry serious health consequences for older women.

Hormone therapy remains one of the most effective strategies for preserving bone density in postmenopausal women, and leading medical societies consider it appropriate for prevention of osteoporosis in healthy women under 60 or within 10 years of menopause.

Cardiovascular health

Estrogen has important protective effects on vascular health. Menopause is associated with an increase in total cholesterol, LDL cholesterol, and triglycerides, changes that peak during late perimenopause and early postmenopause. Blood pressure also tends to rise during the transition. These shifts mean that cardiovascular risk increases meaningfully after menopause, and this is now recognized as a major women’s health issue.

The relationship between hormone therapy and cardiovascular health is nuanced and timing-dependent. For women who initiate hormone therapy during the perimenopause or early postmenopause, observational data have generally supported a favorable cardiovascular effect, or at minimum no harm. The risks are different for women who begin hormone therapy a decade or more after menopause, particularly if there is pre-existing cardiovascular disease.

Alzheimer’s disease and cognitive decline

Estrogen plays a role in brain health, and its decline at menopause has implications for cognitive function that extend well beyond the familiar brain fog of perimenopause. Women account for roughly two-thirds of all Alzheimer’s diagnoses in the United States, a disparity that researchers increasingly believe is at least partly hormonal rather than simply a reflection of women living longer.

The relationship between estrogen and Alzheimer’s risk is strongly timing-dependent. Studies tracking women who began hormone therapy at the time of menopause have found a meaningful reduction in dementia risk, while studies of women who began hormones a decade or more after menopause have found neutral or adverse effects. This is the basis of the “critical window” hypothesis: estrogen appears to be neuroprotective when neurons are healthy at the time of exposure, but the same effect does not hold once neurological changes have already begun. A review of medical records from Kaiser Permanente found that women who started hormones around the time of menopause had a 26% decreased risk of subsequent dementia, while those who started hormones many years after menopause had a 48% increased risk.

Genetic factors also appear to interact with timing. Research has found that women who carry the APOE4 gene variant, which significantly raises Alzheimer’s risk, may have the most to gain from earlier hormone therapy initiation.

This is an evolving area of research, and it reinforces the broader principle that the postmenopause years are not too late for important health conversations, but that earlier action, particularly within the first decade after menopause, tends to yield better outcomes.

Menopause as an Ongoing Clinical Conversation

As previously discussed, one of the most important concepts in modern menopause care is the “therapeutic window”. This is not simply a matter of symptom timing. Starting hormone therapy during this window appears to have a meaningful impact. Importantly, hormone therapy does not need to be routinely discontinued at age 65 for women who are doing well on it and who have had a recent clinical evaluation.

This is why the menopause transition is best understood not as a single problem to solve but as an ongoing conversation with a clinician who understands hormonal health in depth. Ideally, that relationship begins in perimenopause, before symptoms become severe, and continues through postmenopause, adapting as your health picture evolves. A clinician who is expert in the hormonal changes of midlife, and in their downstream health risks, is not simply someone to call when you can no longer tolerate your symptoms. She or he is a partner in managing a multi-decade transition with real consequences for your long-term health.

Taking Yourself Seriously

Any significant change in your menstrual pattern, symptom burden, or overall wellbeing during midlife is worth raising with a knowledgeable provider. You don’t need to wait until you’re clearly postmenopausal, and you don’t need to be suffering significantly to have a conversation about where you are in the transition and what your options are. The questions worth asking at any phase include: What stage am I in? What should I be monitoring? What are my treatment options? And what are the long-term health implications of acting or not acting now?

Specifically, seek an evaluation if you are experiencing:

• Cycles that have become significantly shorter, longer, or more irregular
• Heavy menstrual bleeding that is disrupting your daily life
• Hot flashes or night sweats that affect sleep or functioning
• Sleep disruption that is new or worsening
• Mood changes, anxiety, or depression that are new or significantly worse
• Cognitive changes that feel outside the range of normal stress or fatigue
• Vaginal dryness, discomfort with sex, or changes in urinary function
• Any bleeding after 12 consecutive months without a period, this should always be evaluated promptly

If you feel dismissed or told that your symptoms are simply part of aging without being offered further evaluation or treatment options, it is entirely reasonable to seek a second opinion or a provider who specializes in menopause care.

Frequently Asked Questions About the Menopause Transition

Q: How do I know what phase I’m in?

A: The most reliable marker is your menstrual pattern. Regular cycles suggest you’re still in the reproductive or early transitional stage. Cycles that have become variable (differing by 7 or more days)indicate early perimenopause. Intervals of 60 days or more without a period characterize late perimenopause. After 12 consecutive months with no period, you’ve reached menopause. Hormone levels (FSH, estradiol) can provide supporting information but are less definitive than cycle changes, since hormone levels fluctuate significantly during the transition.

Q: Can I have symptoms for years before my cycle becomes irregular?

A: Yes. Some symptoms can begin in the late reproductive years before cycles become noticeably variable. Hot flashes can also begin in early perimenopause, even while cycles are still relatively regular. Research has identified women whose vasomotor symptoms begin as many as 11 years before their final menstrual period.

Q: Does everyone go through the same phases?

A: Not exactly. While the general framework of reproductive to perimenopausal to postmenopausal stages applies broadly, the timing, duration, and intensity of each phase varies widely between women. Genetics, race, ethnicity, smoking history, BMI, and other factors all influence when the transition begins, how long it lasts, and what symptoms are most prominent. Black women, for example, tend to reach menopause earlier on average and report more frequent and severe vasomotor symptoms than white women. There is no single “normal” timeline.

Q: Is it possible to be in perimenopause for a very long time?

A: Yes. The full perimenopause transition averages four to eight years, but it can be considerably longer for some women. A portion of women experience vasomotor symptoms for ten years or more before and after menopause. There’s no fixed endpoint for how long the transition takes, and waiting it out without support is not the only option.

Q: If I have a hysterectomy, will I go through menopause differently?

A: It depends on what was removed. If your uterus was removed but your ovaries were kept, you will not have periods anymore, but your ovaries will continue to function and you will still go through the hormonal transition at roughly the expected time, you just won’t be able to use cycle changes as a marker. If both ovaries are removed (bilateral oophorectomy), you will enter surgical menopause immediately, regardless of age, with an abrupt hormonal shift that is often more intense than natural menopause.

Q: I’m 56 and still having periods. Is that normal?

A: While the average age of menopause is 51.4, the range of normal is broad. Some women reach menopause in their late 40s; others not until their mid-50s. If you are still having regular periods at 56, it’s worth discussing with your provider: not necessarily because something is wrong, but to rule out any underlying causes and to understand what to expect. Late menopause (after 55) has some associations with a longer window of estrogen exposure, which may carry both benefits and considerations worth discussing.

Q: What does “early menopause” mean, and should I be concerned?

A: Early menopause refers to menopause occurring before age 45. Premature menopause (primary ovarian insufficiency) refers to loss of ovarian function before age 40. Both affect about 10% of women in aggregate. Because estrogen deficiency begins earlier in these women, the long-term health risks associated with estrogen loss are greater. Hormone therapy is generally strongly recommended for women with early or premature menopause, at minimum until the average age of natural menopause.

The Bottom Line

Menopause is not a single event and it is not simply about hot flashes. It is a multi-year, multi-phase biological process with real implications for how you feel day-to-day and for your long-term health, and you deserve a provider who treats it that way.

This article is for informational and educational purposes and does not constitute medical advice. Please consult a qualified healthcare provider for evaluation and treatment recommendations specific to your situation.

References

1. Harlow SD, Gass M, Hall JE, et al.; STRAW +10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–1168. doi: 10.1210/jc.2011-3362

2. El Khoudary SR, Aggarwal B, Beckie TM, et al.; on behalf of the American Heart Association Prevention Science Committee. Menopause transition and cardiovascular disease risk: implications for timing of early prevention — a scientific statement from the American Heart Association. Circulation. 2020;142:e506–e532. doi: 10.1161/CIR.0000000000000912

3. The Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767–794. doi: 10.1097/GME.0000000000002028

4. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. doi: 10.1172/jci.insight.124865

5. Bromberger JT, Epperson CN. Depression during and after the perimenopause: impact of hormones, genetics, and environmental determinants of disease. Obstet Gynecol Clin North Am. 2018;45:663–678. doi: 10.1016/j.ogc.2018.07.007

6. American Urological Association. Genitourinary syndrome of menopause: clinical guideline. Published 2025. Available at: www.auanet.org

7. Whiteley J, daCosta DiBonaventura M, Wagner JS, Alvir J, Shah S. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Women’s Health. 2013;22(11):983–990. doi: 10.1089/jwh.2012.3719

8. Yang W, Toriola AT. Menopausal hormone therapy use among postmenopausal women in the United States, 2009–2020. JAMA Health Forum. 2024;5(9):e243128. doi: 10.1001/jamahealthforum.2024.3128

9. Shapley M, Blagojevic M, Jordan KP, Croft PR. The spontaneous resolution of heavy menstrual bleeding in the perimenopausal years. BJOG. 2012;119:545–553. doi: 10.1111/j.1471-0528.2012.03282.x